"The
Report PharmaPoint: Allergic Rhinitis - Global Drug Forecast and
Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz
Allergic Rhinitis (AR) is
becoming an increasingly prevalent condition, with the most common
form being moderate to severe in nature (Baena-Cagnani et al., 2015).
According to the European Academy of Allergy and Clinical Immunology
(EAACI), 50% of Europeans will suffer from an allergy by 2027
(Papadopoulos et al., 2012). The allergic rhinitis (AR) market has
declined very slowly over the past decade, as has it become saturated
with relatively efficacious standard therapies, such as
antihistamines (AHs), intranasal corticosteroids (INCS), and
leukotriene receptor antagonists (LRAs), and has also been facing
increasing generic competition. Despite the rising prevalence of AR,
and a large patient population that is dissatisfied with the current
treatment options, the market size for symptomatic therapies alone is
set to shrink, as the remaining branded products lose patent
protection. There is an increasing shift in the transfer of
prescription AR products to over-the-counter (OTC) status, which is
driving patients to pharmacies rather than to physicians, further
diluting the prescription AR market. The immense, crowded generic AR
market has been largely unappealing to drug manufacturers.
Consequently, only two symptomatic therapies are expected to launch
before 2024.
View
Report At :http://www.marketresearchreports.biz/analysis/483154
Highlights
Key Questions Answered
- Allergic Rhinitis symptoms
can be controlled in the majority of patients using the current
standard therapies. Nevertheless, in around 20% of people with
allergic rhinitis, the disease remains symptomatic and inadequately
controlled. Therefore, there are considerably high unmet needs within
the indication. What are the main unmet needs in this market?
- The current late-stage
allergic rhinitis pipeline is sparse. Will the late-stage symptomatic
drugs make a significant impact on the allergic rhinitis market? What
strategies are drug developers undertaking to penetrate this
difficult but potentially very lucrative market? How will
immunotherapies affect the market landscape?
- The prevalence of
environmental diseases, including allergic rhinitis, is increasing
worldwide, with an estimated 46 million US citizens are likely to
suffer from allergic rhinitis in 2024. How will epidemiological
changes impact the growth of the future market?
Key Findings
- The main driver of growth in
the AR market will be the introduction of several AIT tablets: Mercks
Grastek (grass), Ragwitek (ragweed), and Mitizax (house dust mite
[HDM]) tablets, as well as Greers Oralair (grass) in the US. These
new products overcome the inconvenience of conventional subcutaneous
immunotherapies (SCITs).
- The major global barrier for
the AR market will be the increasing push for patients to
self-medicate using OTC drugs will decrease the prescription AR drug
market size.
- There is little room for new
entrants, as the market is well-served by a wealth of symptomatic
therapies. Since the competition is increasing, the market for AR
therapies is becoming increasingly less lucrative. Also, there are
currently no breakthrough symptomatic therapy products in clinical
development.
-
The remaining clinical unmet needs in this market include the
requirement for more efficacious products, and the underserved area
of causative therapies, such as immunotherapies, which target the
underlying cause of the disease.
Download
Sample copy of this Report at
Scope
- Overview of AR, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized AR therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the AR
therapeutics market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, and detailed analysis of late-stage
pipeline drugs.
- Analysis of the current and
future market competition in the global AR therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global AR
therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global AR
therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global AR therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1
Table of Contents 12
1.1
List of Tables 18
1.2
List of Figures 21
2
Introduction 22
2.1
Catalyst 22
2.2
Related Reports 23
2.3
Upcoming Related Reports 23
3
Disease Overview 24
3.1
Etiology and Pathophysiology 24
3.2
Symptoms 27
3.3
Classification 28
3.3.1
Seasonal and Perennial AR 28
3.3.2
ARIA Classification of AR 28
3.4
Diagnosis 29
3.5
Quality of Life 31
4
Epidemiology 32
4.1
Disease Background 32
4.2
Risk Factors and Comorbidities 33
4.2.1
A family history of AR is a strong predictor for AR in children and
adults 34
4.2.2
Exposure to allergens in the environment increases the risk for AR 35
4.2.3
Urban living elevates the risk for AR 35
4.2.4
Comorbidities 36
4.3
Global and Historical Trends 38
4.3.1
US 38
4.3.2
5EU 39
4.3.3
Japan 40
4.4
Forecast Methodology 41
4.4.1
Sources Used 43
4.4.2
Sources Not Used 46
4.4.3
Forecast Assumptions and Methods 46
4.5
Epidemiological Forecast for AR (2013-2023) 49
4.5.1
Total Prevalent Cases of AR 49
4.5.2
Age-Specific Total Prevalent Cases of AR 51
4.5.3
Sex-Specific Total Prevalent Cases of AR 53
4.5.4
Age-Standardized Total Prevalence of AR 55
4.5.5
Distribution of Total Prevalent Cases of AR by Severity 57
4.5.6
Distribution of Total Prevalent Cases of AR by Type 58
4.5.7
Distribution of Total Prevalent Cases of AR Sensitized to Specific
Allergens 59
4.6
Discussion 60
4.6.1
Epidemiological Forecast Insight 60
4.6.2
Limitations of the Analysis 60
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment